These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27809751)

  • 1. Structure and Function of Small Non-Peptide CRF Antagonists and their Potential Clinical Use.
    Fahmy H; Kuppast B; Ismail MT
    Curr Mol Pharmacol; 2017; 10(4):270-281. PubMed ID: 27809751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Don't stress about CRF: assessing the translational failures of CRF
    Spierling SR; Zorrilla EP
    Psychopharmacology (Berl); 2017 May; 234(9-10):1467-1481. PubMed ID: 28265716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications.
    McCarthy JR; Heinrichs SC; Grigoriadis DE
    Curr Pharm Des; 1999 May; 5(5):289-315. PubMed ID: 10213797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of 2-imino and 2-hydrazono thiazolo[4,5-d]pyrimidines as corticotropin releasing factor (CRF) antagonists.
    Teleb M; Kuppast B; Spyridaki K; Liapakis G; Fahmy H
    Eur J Med Chem; 2017 Sep; 138():900-908. PubMed ID: 28750312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of substituted pyrimidines as corticotropin releasing factor (CRF) receptor ligands.
    Kuppast B; Spyridaki K; Liapakis G; Fahmy H
    Eur J Med Chem; 2014 May; 78():1-9. PubMed ID: 24675175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in corticotropin-releasing factor-1 antagonist development.
    Zorrilla EP; Koob GF
    Drug Discov Today; 2010 May; 15(9-10):371-83. PubMed ID: 20206287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of new thiazolo[4,5-d]pyrimidines as Corticotropin releasing factor modulators.
    Kuppast B; Spyridaki K; Lynch C; Hu Y; Liapakis G; Davies GE; Fahmy H
    Med Chem; 2014; 11(1):50-9. PubMed ID: 25059547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-peptidic CRF1 receptor antagonists for the treatment of anxiety, depression and stress disorders.
    Kehne J; De Lombaert S
    Curr Drug Targets CNS Neurol Disord; 2002 Oct; 1(5):467-93. PubMed ID: 12769601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The corticotropin-releasing factor (CRF) family of neuropeptides in inflammation: potential therapeutic applications.
    Gravanis A; Margioris AN
    Curr Med Chem; 2005; 12(13):1503-12. PubMed ID: 15974983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of CRF1 receptor antagonists as antidepressants and anxiolytics: progress to date.
    Valdez GR
    CNS Drugs; 2006; 20(11):887-96. PubMed ID: 17044726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective Clinical Applications of CRF Peptide Antagonists.
    Rivier JE
    Curr Mol Pharmacol; 2017; 10(4):264-269. PubMed ID: 28103781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacology of DMP696 and DMP904, non-peptidergic CRF1 receptor antagonists.
    Li YW; Fitzgerald L; Wong H; Lelas S; Zhang G; Lindner MD; Wallace T; McElroy J; Lodge NJ; Gilligan P; Zaczek R
    CNS Drug Rev; 2005; 11(1):21-52. PubMed ID: 15867951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists.
    Gilligan PJ; He L; Clarke T; Tivitmahaisoon P; Lelas S; Li YW; Heman K; Fitzgerald L; Miller K; Zhang G; Marshall A; Krause C; McElroy J; Ward K; Shen H; Wong H; Grossman S; Nemeth G; Zaczek R; Arneric SP; Hartig P; Robertson DW; Trainor G
    J Med Chem; 2009 May; 52(9):3073-83. PubMed ID: 19361210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corticotropin-releasing factor 1 receptor antagonists: a patent review.
    Williams JP
    Expert Opin Ther Pat; 2013 Aug; 23(8):1057-68. PubMed ID: 23642023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, Synthesis, and Biological Evaluations of Novel Thiazolo[4,5-d]pyrimidine Corticotropin Releasing Factor (CRF) Receptor Antagonists as Potential Treatments for Stress Related Disorders and Congenital Adrenal Hyperplasia (CAH).
    Islam MR; Markatos C; Pirmettis I; Papadopoulos M; Karageorgos V; Liapakis G; Fahmy H
    Molecules; 2024 Aug; 29(15):. PubMed ID: 39125051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corticotropin-releasing factor receptor antagonists in affective disorders and drug dependence-- an update.
    Steckler T; Dautzenberg FM
    CNS Neurol Disord Drug Targets; 2006 Apr; 5(2):147-65. PubMed ID: 16611089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential uses of corticotropin-releasing hormone antagonists.
    Zoumakis E; Rice KC; Gold PW; Chrousos GP
    Ann N Y Acad Sci; 2006 Nov; 1083():239-51. PubMed ID: 17148743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3D-QSAR study of corticotropin-releasing factor 1 antagonists and pharmacophore-based drug design.
    Ye Y; Liao Q; Wei J; Gao Q
    Neurochem Int; 2010 Jan; 56(1):107-17. PubMed ID: 19782115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The corticotropin-releasing factor (CRF)(1) receptor antagonists CP154,526 and DMP695 inhibit light-induced phase advances of hamster circadian activity rhythms.
    Gannon RL; Millan MJ
    Brain Res; 2006 Apr; 1083(1):96-102. PubMed ID: 16551464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corticotropin-releasing hormone modulators and depression.
    Holsboer F
    Curr Opin Investig Drugs; 2003 Jan; 4(1):46-50. PubMed ID: 12625028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.